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Abstract
Introduction: Vitamin D has been determined to have some effects on b cell function and insulin sensitivity, and it is known that type 2 
diabetes mellitus and hyperparathyroidism can cause obesity. The aim of our study was to investigate if vitamin D deficiency without 
diabetes mellitus and metabolic syndrome is associated with obesity and abdominal obesity.
Material and methods: The study included 276 healthy premenopausal women. To exclude other causes of obesity, postmenopausal 
women and subjects with diabetes mellitus and metabolic syndrome were excluded. Women were divided into two groups depending 
on their 25-hydroxyvitaminD3 [25(OH)D3] levels: subjects with vitamin D deficiency (Group 1) and subjects without vitamin D deficiency 
(Group 2). Body mass index (BMI), waist circumference (WC), and waist-to-hip ratio (WHR) were compared between the two groups.
Results: BMI, WC, WHR, rates of obesity, and abdominal obesity according to WC and WHR of Group 2 were lower than those of Group 1 
(p = 0.0005, p = 0.0001, p = 0.0045, p = 0.032, p = 0.002, p = 0.011, respectively). 25(OH)D3 levels negatively correlated with BMIs (r = –0.480, 
p < 0.0001), WCs (r = –0.480, p < 0.0001) and WHRs (r = –0.312, p < 0.05). There were no differences between serum parathormone, 
calcium and phosphorus levels of Group 1 and 2 (p = 0.239, p = 0.354, p = 0.95, respectively).
Conclusion: Vitamin D deficiency without diabetes mellitus and hyperparathyroidism may be associated with obesity and abdominal 
obesity. (Pol J Endocrinol 2012; 63 (3): 196–201)
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Streszczenie
Wstęp: Wykazano, że witamina D wpływa na czynność komórek b i wrażliwość na insulinę. Wiadomo również, że cukrzyca typu 2 
i nadczynność przytarczyc mogą powodować otyłość. Celem badania było ustalenie, czy niedobór witaminy D u osób bez cukrzycy 
i zespołu metabolicznego wiąże się z otyłością i otyłością brzuszną.
Materiał i metody: Do badania włączono 276 zdrowych kobiet przed menopauzą. W celu wyeliminowania innych przyczyn otyłości 
z badania wykluczono kobiety po menopauzie, chore na cukrzycę i osoby, u których rozpoznano zespół metaboliczny. Uczestniczki 
badania podzielono na 2 grupy w zależności od stężenia witaminy 25-hydroksyD3 [25(OH)D3]: grupa 1 — osoby z niedoborem witaminy 
D, grupa 2 — osoby z prawidłowym stężeniem witaminy D. Porównano wskaźniki masy ciała (BMI, body mass index), obwody talii (WC, 
waist circumference) i współczynniki talia/biodra (WHR, waist-to-hip ratio) w obu grupach.
Wyniki: Wartości BMI, WC, WHR, odsetek osób otyłych i częstość otyłości brzusznej, określone na podstawie WC i WHR, były mniejsze 
w grupie 2, niż w grupie 1, (odpowiednio p = 0,0005; p = 0,0001; p = 0,0045; p = 0,032; p = 0,002; p = 0,011). Stężenia 25(OH)D3 były 
ujemnie skorelowane z wartościami BMI (r = –0,480; p < 0,0001); WC (r = –0,480; p < 0,0001) i WHR (r = –0,312; p < 0,05). Nie stwierdzono 
różnic między grupami pod względem stężeń parathormonu, wapnia i fosforu w surowicy (odpowiednio p = 0,239; p = 0,354; p = 0,95).
Wnioski: Niedobór witaminy D u osób bez cukrzycy i nadczynności przytarczyc może się wiązać z otyłością i otyłością brzuszną. (En-
dokrynol Pol 2012; 63 (3): 196–201)
Słowa kluczowe: otyłość, otyłość brzuszna, niedobór witaminy D, 25-hydroksyD3, wskaźnik masy ciała
Introduction
Humans get vitamin D from exposure to sunlight, from 
their diet, and from dietary supplements. Solar ultravio-
let B radiation (wavelength, 290 to 315 nm) penetrates 
the skin and converts 7-dehydrocholesterol to previta-
min D3, which is rapidly converted to vitamin D3 [1–5].
The best food sources of vitamin D are fatty fish 
or their liver oils; however, small amounts are also 
found in butter, cream and egg yolk. Human and 
cows’ milk are poor sources of vitamin D [6]. Vitamin 
D from the skin and diet is metabolised in the liver 
to 25hydroxyvitamin D3 [25(OH)D3], which is used to 
determine the vitamin D status of a patient; 25(OH)D3 
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is metabolised in the kidneys by the enzyme 25-hy-
droxyvitamin D-1a-hydroxylase to its active form, 
1,25-dihydroxyvitamin D3. The renal production of 
1,25dihydroxyvitamin D3 is tightly regulated by se-
rum parathyroid hormone, calcium and phosphorus 
levels [5].
The action of vitamin D on the small intestine and 
the bone is well known [1, 3, 5]. In the bone, vitamin 
D induces the differentiation of pre-osteoclasts to ma-
ture osteoclasts, ultimately promoting the removal of 
calcium and phosphorus from the bone [5].
In recent years, discussion of the actions of vitamin D 
has extended well beyond calcium metabolism. Nowa-
days, there is great interest in its role in decreasing the 
risk of many chronic diseases, including obesity which 
is associated with chronic inflammation in adipose 
tissue. It has been shown that vitamin D regulates cal-
cium metabolism through its endocrine function and 
its noncalciotropic effects such as cellular differentia-
tion and replication in many organs via its paracrine 
and autocrine role. These noncalciotropic functions 
comprise the immune system, liver, skeletal muscles, 
adipocytes and endocrine pancreas which have im-
portant roles in obesity and diabetes mellitus [7–12]. 
Vitamin D deficiency has been shown to impair insulin 
synthesis and secretion in human and animal models of 
diabetes, suggesting a role in the development of type 2 
diabetes, which is one of the common causes of obesity 
and abdominal obesity [6, 13].
Moreover, vitamin D decreases production of tu-
mour necrosis factor a (TNF-a) which leads to impaired 
glucose metabolism in adipose tissue and skeletal 
muscle [14]. Besides, low levels of 25(OH)D3 result in 
hyperparathyroidism and are among the endocrine 
derangements of adult obesity [15].
In this study, we hypothesise that obesity and 
abdominal obesity are more common in vitamin D 
deficiency independent of diabetes mellitus. With this 
aim, after excluding patients with diabetes mellitus and 
metabolic syndrome, which are common causes of obe-
sity and abdominal obesity, we investigated body mass 
index (BMI), waist circumference (WC), waist-to-hip 
ratio (WHR), rates of obesity and abdominal obesity 
in subjects with and without vitamin D deficiency and 
compared them with one another.
Materials and methods
This study was approved by our institutional Ethics 
Committee (approval date and number: 21 Feb 2008, 
44/E) and the study subjects have therefore been as-
sessed in accordance with the ethical standards set 
out in the Declaration of Helsinki. All subjects gave 
informed consent prior to their inclusion in the study.
Subjects
Two hundred and seventy six healthy premenopausal 
female volunteers were included in the present study. 
It has been determined that the loss of oestrogen at the 
menopause causes weight gain [16]. Therefore only 
premenopausal females were included in the study. 
According to their serum 25 (OH) D3 vitamin levels, 
subjects were divided into two subgroups: 162 subjects 
(58.69%) with vitamin D deficiency (the VDD Group), 
and 114 subjects (41.30%) without vitamin D deficiency 
(the NVDD Group).
Serum levels of calcium, phosphorus, parathormone 
(PTH) and 25 hydroxyvitamin D3 [25 (OH) D3] were 
measured in all subjects. Hip and waist circumfer-
ences were determined and BMIs and WHRs of all the 
participants were calculated. To exclude subjects with 
type 2 diabetes mellitus and metabolic syndrome (the 
diagnosis of metabolic syndrome was determined by 
the criteria of the Adult Treatment Panel III guidelines) 
[17], fasting and postprandial glucose levels, WCs, blood 
pressures, triglyceride and high density lipoprotein 
cholesterol (HDL-C) levels were measured. To exclude 
postmenopausal women, serum oestradiol, follicle-stim-
ulating hormone (FSH), and luteinising hormone (LH) 
levels of all the subjects were measured. Subjects with 
diabetes mellitus, metabolic syndrome, liver disorders, 
thyroid dysfunction, renal disorders, congestive heart 
failure, lactose or gluten intolerance (coeliac disease), 
metabolic bone disorders, primary hyperparathy-
roidism, epilepsy on anticonvulsant therapy, or who 
were on other medications that might alter 25(OH)D3 
vitamin, 1,25(OH)2D3 vitamin metabolism, body weight, 
and thyroid functions, or subjects being treated with 
supplemental calcium, vitamin D, steroids, thiazides, or 
who had recently quit smoking , pregnant women, and 
those currently involved in a weight loss programme, 
were excluded from the study.
Body mass index was calculated as body weight (kg) 
divided by height (m) squared, and obesity was defined 
as BMI of 30 or above (kg/m2) [18–20].
Waist circumferences were measured at the plane 
between anterior superior iliac spines and lower costal 
margins at the narrowest part of the waistline while 
patients were standing during slight expiration. For 
women, a WC > 88 cm was accepted as abdominal 
obesity [19–21].
Hip circumferences were measured horizontally 
over the farthest points of trochanters while standing 
with feet 20–30 cm apart. A WHR of > 0.85 was accepted 
as abdominal obesity [19, 20].
Since decreased physical activity is thought to play 
an important role in the pathogenesis of obesity [21], 
all the subjects were questioned about their normal 
physical activity. If they did exercise, they were also 
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questioned about how often they exercised regularly. 
Regular exercise was defined as a minimum of 45 min-
utes walking, at least four days a week or its calorie 
equivalent [16].
The study was conducted between October 2008 
and February 2009.
Laboratory investigation
Since the key diagnostic test in vitamin D deficiency is 
demonstration of a decreased serum 25 hydroxyvitamin 
D3 [25 (OH) D3] vitamin value, we determined serum 
25 (OH) D3 level for vitamin D deficiency. The 1,25 
(OH)2D3 levels may be normal in vitamin D deficiency, 
because of the maximal stimulation of 1ahydroxylase 
by the low serum phosphorus and high PTH levels [22]. 
Serum levels of 25(OH) D3 lower than 20 ng/ml were 
accepted as vitamin D deficiency [5, 23].
To measure serum 25 (OH)D3 levels, venous blood 
samples were collected into plain tubes, and serum 
was separated and stored at –70 °C for up to a week 
until analysis. Levels of 25 (OH)D3 were estimated 
using a kit 25 (OH)D3-Ria-CT (Brussels, Belgium). The 
treated samples were then assayed using a competitive 
binding radioimmunoassay (RIA) technique. Serum 
PTH (reference interval: 15-65 pg/mL); LH (reference 
interval for follicular phase: 2.4–12.6 mU/mL; for luteal 
phase: 1–11.4 mU/mL, for midcycle: 14–96 mU/mL); FSH 
(reference interval for follicular phase: 3.5–12.5 mU/mL; 
for luteal phase: 1.7–7.7 mU/mL, for midcycle: 4.7– 
–21.5 mU/mL); and oestradiol levels (reference interval 
for follicular phase: 12.5–166 pg/mL; for luteal phase: 
43.8–211 pg/mL, for midcycle: 85.5–498 pg/mL) were 
measured by electrochemiluminescent immunoassay 
(ECLIA) (Modular Analytics E170, Roche Diagnostics, 
Mannheim, Germany). Other biochemical parameters 
included in this study were glucose (reference inter-
val: 70–100 mg/dL), triglyceride (reference interval: 
0–150 mg/dL), HDL (reference interval: 35–55 mg/dL), 
albumin (reference interval: 3.5–5.2 gr/dL), calcium 
(reference interval: 8.8–10.6 mg/dL), and phosphorus 
(reference interval: 2.5–4.5 mg/dL). Serum levels of these 
biochemical parameters were determined according to 
standard laboratory procedures on an auto-analyser 
Olympus 2700 (Tokyo, Japan). Corrected calcium levels 
were calculated on the basis of albumin levels.
Statistical analysis
All analyses in the statistical evaluation were carried 
out with SPSS v.13.0 software. VDD and NVDD groups 
were compared with independent samples t-test for 
continuous variables which show a normal distribu-
tion according to Shapiro-Wilk and Kolmo gorov- 
-Smirnov tests. Chi-square test was used for categori-
cal variables to compare two groups. Spearman cor-
relations were used to assess the correlations between 
BMI and 25(OH)D3, between WC and 25(OH)D3 and 
between WHR and 25(OH)D3 as well as the potential 
covariates. p ≤ 0.05 was considered to have statistical 
significance.
Results
The present study included 162 female subjects with 
vitamin D deficiency (the VDD Group) and 114 without 
vitamin D deficiency (the NVDD Group). Characteristics 
of all the subjects are set out in Table 1. There were no 
significant differences in the regular exercise rates or the 
ages of the subjects between the VDD and the NVDD 
groups (p = 0.076, p = 0.087).
Body mass index, WC, WHR, rates of obesity, and 
abdominal obesity according to WC and WHR of 
the NVDD group were lower than those of the VDD 
group (p = 0.0005, p = 0.0001, p = 0.0045, p = 0.032, 
p = 0.002, p = 0.011, respectively) (Table I). However, 
there were no significant differences between serum 
calcium, phosphorus or PTH levels of the NVDD and 
VDD groups (p = 0.22, p = 0.92, p = 0.23, respec-
tively) (Table I). Neither were there any significant 
differences between serum calcium, phosphorus or 
PTH levels of obese and nonobese subjects in the VDD 
group (p = 0.354, p = 0.95, p = 0.239, respectively) 
(Table II). In all subjects, 25(OH)D3 vitamin levels 
were negatively correlated with BMIs, WCs and 
WHRs (r = –0.480, p < 0.0001; r = –0.416, p < 0.0001; 
r = –0.312, p ≤ 0.05, respectively).
Discussion
In recent years, there has been a worldwide increase in 
the prevalence of obesity, a problem that continues to 
grow. The same period has also exhibited an increasing 
interest in the role of vitamin D in chronic diseases [24], 
including obesity [25, 26].
Low serum 25(OH)D3 is known to deteriorate cel-
lular function in many tissues, including endocrine 
pancreas, which are involved in obesity and type 2 
diabetes mellitus (T2DM). Vitamin D deficiency has 
been linked to obesity, whether obesity is assessed by 
body mass index (BMI) or waist circumference. Central 
obesity, using the waist as the surrogate, is associated 
with metabolic syndrome, insulin resistance, T2DM and 
atherosclerotic cardiovascular disease [13, 27]. Different 
mechanisms have been suggested about the association 
between vitamin D deficiency and obesity. Previously 
reviewed mechanisms include the following:
1) low vitamin D3 may impair insulin action, glucose 
metabolism and various other metabolic processes in 
adipose and lean tissue [13];
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2) fat soluble vitamin D3 is sequestered in large adi-
pose compartment and low in serum [13];
3) obese people may be sensitive about their body 
shape, minimising their skin exposure to view and 
sunlight (not tested) [13];
4) abnormal serum calcium metabolism has been 
associated with weight gain [28], and a high calcium 
intake is believed to prevent obesity [29];
5) 1,25 (OH)2D3 is reported to inhibit the expres-
sion of adipocyte uncoupling protein 2 (UCP-2), which 
would stimulate lipogenesis and inhibit lipolysis [30, 31];
6) Physiologic increase in parathyroid hormone lev-
els in response to hypovitaminosis D state is believed to 
increase intracellular calcium in adipocytes, which leads 
to increased lipogenesis and weight gain [32];
7) obesity is associated with chronic inflammation 
in adipose tissue, as evidenced by increased levels of 
cytokines including tumour necrosis factor a (TNF-a), 
and accumulation and activation of macrophages and 
T cells [33]. Recently in a study performed in mice, 
TNF-a has been determined to promote lipogenesis, 
induce lipolysis [34] and interfere with insulin signal-
ling, which would lead to impaired glucose metabolism 
in adipose tissue and skeletal muscle [14].
It has been proposed that proinflammatory cy-
tokines are causally linked to the development of insulin 
resistance [35, 36] and islet cell inflammation which is 
involved in the regulation of b-cell function in type 2 
diabetes [14, 37]. Th1 cell-derived interferon (IFN)-g has 
been determined to regulate fat inflammation and glu-
cose homeostasis in mice [33]. Vitamin D receptors are 
found in significant concentrations in the T lymphocyte 
and macrophage population which have been detected 
in adipose tissue with increased infiltration in obesity.
Vitamin D decreases not only the proliferation of 
purified T (helper) h cells but also the production of 
important cytokines in the pathogenesis of obesity such 
as interferon (IFN)-g and TNF-a [38, 39].
Konradsen et al. [40] who studied 2,187 subjects 
recruited from a metabolic and medical lifestyle man-
Table II. Comparisons of serum calcium, phosphorus and PTH levels of obese and non-obese subjects with vitamin D deficiency (VDD)
Tabela II. Porównanie stężeń wapnia, fosforu i PTH w surowicy między otyłymi i nieotyłymi kobietami z niedoborem witaminy D (VDD)
Obese subjects with VDD (n = 42) Non-obese subjects with VDD (n = 120) p
25(OH)D3 vitamin [ng/mL] 10.05 ± 5.35 9.72 ± 5.13 0.84
Calcium [mg/dL] 9.51 ± 0.31 9.40 ± 0.40 0.35
Phosphorus [mg/dL] 3.59 ± 0.56 3.58 ± 0.54 0.24
PTH [pg/mL] 37.56 ± 8.26 42.29 ± 13.97 0.95
PTH — parathormone
Table I. Comparison of characteristics of subjects with and without vitamin D deficiency (VDD)
Tabela I. Porównanie charakterystyki osób z niedoborem i bez niedoboru witaminy D (VDD, vitamin D deficiency)
Subjects with VDD (n = 162) Subjects without VDD (n = 114) p
Age  33.66 ± 5.73  31.55 ± 5.86 0.879
Rates of the subjects who do exercise on  
a regular basis
24 (14.8%) 3 (2.6%) 0.076
25(OH)D3 vitamin [ng/mL]  9.80 ± 5.14  54.29 ± 24.17 0.0005
Calcium [mg/dL]  9.42 ± 0.38  9.32 ± 0.4 0.22
Phosphorus [mg/dL]  3.58 ± 0.54  3.59 ± 0.41 0.92
PTH [pg/mL]  41.06 ± 12.83  44.61 ± 14.67 0.23
BMI  28.16 ± 5.56  23.22 ± 4.47 0.0005
WC [cm]  88.19 ± 11.75  77.71 ± 12.28 0.0001
WHR  0.82 ± 0.07  0.77 ± 0.08 0.0045
Rate of obesity 42 (25.9%) 9 (8.1%) 0.032
Rate of abdominal obesity according to WC 75 (46.3%) 18 (15.8%) 0.002
Rate of abdominal obesity according to WHR 48 (29.6%) 9 (7.9%) 0.011
BMI — body mass index; WC — waist circumference; WHR — waist-to-hip ratio; PTH — parathormone
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agement clinic in Norway, observed that increasing BMI 
was accompanied by a significant reduction in serum 
25(OH)D3 and 1,25(OH)2D3 concentrations, and that 
those with a BMI of > 39.9 kg/m2 had a 24% lower serum 
25(OH)D3 concentration and an 18% lower 1,25(OH)2D3 
concentration than those with a BMI of < 25 kg/m2. 
These results support the findings of Rodriguez’s study, 
in which it was noted that a BMI of < 27.7 kg/m2 fa-
voured a serum vitamin D concentration of > 90 nmol/l. 
Furthermore, Rodriguez found a negative and signifi-
cant correlation between 25(OH)D3 concentrations and 
BMI in women with BMI ≥ 30 kg/m2 [25].
Worstman et al. [41] also found a similar association 
when they studied 13 obese (BMI > 30 km/m2) white 
individuals and 13 controls to evaluate the serum levels 
of 25(OH)D3 and its response after exposure to UVB 
radiation or an oral dose of vitamin D2. They reported 
that BMI was inversely correlated with serum 25(OH)D3 
concentrations after irradiation, and that the increase in 
vitamin D3 levels was 57% less in obese than in nonobese 
subjects post irradiation to UVB rays. This finding sug-
gests that the subcutaneous fat, which is known to store 
vitamin D3, sequesters more of the synthesised vitamin 
D3 in obese than in nonobese subjects, because there is 
more fat available for this process.
Rodriguez reported that women who had high 
25(OH)D3 levels, had lower BMIs, and also had smaller 
waist circumferences, than women who had low 
25(OH)D3 levels [25]. These results comply with those 
reported by McGill [13], who, in a study of 250 ambulant 
New Zealanders aged > 18 years with a BMI of 28– 
–50 kg/m2 reported a reduction of 0.29 nmol/L (p = 0.01) 
in serum 25(OH)D3 for every 1 cm increase in waist cir-
cumference. This finding highlights well the relationship 
between adiposity and serum 25(OH)D3 concentration, 
since waist circumference is a better marker of abdomi-
nal fat accumulation than BMI [42].
In the large USA NHANES dataset, Ford et al. found 
that abdominal obesity as measured by waist circumfer-
ence alone, in addition to metabolic syndrome, was re-
lated to low 25(OH)D3, notably affecting mixed-ethnicity 
participants equally [43].
In the present study, BMI, WC and WHR were 
higher, and obesity and abdominal obesity were com-
moner, in subjects with vitamin D deficiency than in 
subjects without vitamin D deficiency.
In their studies, Alemzadeh et al. observed that 
subjects with hypovitaminosis D had decreased insulin 
sensitivity compared to vitamin D–sufficient subjects, 
corresponding to significantly higher BMI and fat mass 
in the subjects with hypovitaminosis D. Consequently, 
it was determined that lower serum 25(OH) D3 in 
obese people was most likely the cause of higher intact 
(i)PTH concentrations; and serum iPTH levels were 
positively correlated with the degree of adiposity and 
were higher only in the vitamin D-deficient and insuf-
ficient subjects compared to the vitamin D–sufficient 
subjects [15, 44–47].
However, in the present study, as an interesting 
finding, no difference was found between serum PTH 
levels of the subjects with and without vitamin D de-
ficiency. This finding could be explained by blunted 
parathyroid hormone response to vitamin D deficiency 
by hypomagnesaemia, which means that parathyroid 
hormone levels are often normal when 25-hydroxy-
vitamin D3 levels fall below 20 ng/mL [5].
Thus, we suggest that vitamin D deficiency is 
associa ted with obesity and abdominal obesity indepen-
dently of primary and secondary hyperparathyroidism 
in response to vitamin D deficiency. However, we did 
not determine serum magnesium levels of the subjects 
with and without vitamin D deficiency. This is a weak-
ness of our study.
Chiu et al. observed a positive correlation between 
vitamin D status and insulin sensitivity index in 
adults. In addition, they showed that vitamin D levels 
negatively correlated with both first and second phase 
insulin responses during a hyperglycaemic clamp and 
glucose levels during an oral glucose tolerance test. 
Thus, they suggested that subjects with hypovitamino-
sis D displayed more impaired b-cell function causing 
impaired glucose homeostasis, and increased risk of 
developing insulin resistance and metabolic syndrome, 
compared to vitamin D-sufficient subjects [48].
Although some studies have been conducted about 
the association between vitamin D deficiency and obe-
sity, our study is important and different from others, 
because in our study, obesity and abdominal obesity 
were commoner in vitamin D-deficient subjects who 
did not have other important causes of obesity such 
as diabetes mellitus, metabolic syndrome [16, 41] and 
hyperparathyroidism [32]. Hyperparathyroidism 
causes obesity by increasing intracellular calcium in 
adipocytes, which leads to increased lipogenesis and 
weight gain [32].
Conclusions
In conclusion, we suggest that vitamin D deficiency 
may be associated with obesity and abdominal obesity 
independently of its effects on T2DM, metabolic syn-
drome and hyperparathyroidism. Determining vitamin 
D levels may be beneficial for obese and abdominally 
obese people. Vitamin D administration in the winter 
to obese and abdominally obese people with vitamin 
D deficiency is also a subject worth investigating, espe-
cially for countries like ours whose food products are not 
supplemented with vitamin D. However, it may be bet-
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ter for all countries to supplement food products with 
vitamin D to prevent inflammatory diseases including 
obesity which have been linked to vitamin D deficiency.
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